Format

Send to

Choose Destination
Autoimmun Rev. 2014 Jun;13(6):678-84. doi: 10.1016/j.autrev.2014.01.051. Epub 2014 Jan 15.

Putting the value into biosimilar decision making: the judgment value criteria.

Author information

1
Department of Medicine, Universidade Federal de São Carlos. Electronic address: mirhelen@terra.com.br.
2
Adjunct Division of Immunology/Rheumatology, Stanford University School of Medicine. Electronic address: vstrand@aol.com.
3
Department of Medicine, Universidade do Estado do Rio de Janeiro. Electronic address: roger.a.levy@gmail.com.
4
Department of Medicine, Universidade do Estado do Rio de Janeiro. Electronic address: denizarvianna@gmail.com.

Abstract

Uncertainties remain the key issue surrounding biosimilars, although decisions regarding their use must be made. The challenges for policymakers, doctors, patients and others seeking to navigate in the uncharted waters of biosimilars must be clarified. At the most basic level, scientific understanding of the issue remains limited and when making decisions, policymakers must consider all those affected by health policy decisions, particularly the ultimate recipients of these medicines: the patients. The biosimilar-value chain relies on measurement of comparabilities. The goal is to demonstrate how, from a molecular perspective, closely similar they are or are not and how potential small differences may be relevant to clinical outcomes. To critically understand these points, this conceptual paper will present a knowledge-value chain and discuss each dimension assigning value in the decision making process re-utilization of biosimilars.

KEYWORDS:

Biosimilars; Decision process; Immunogenicity; Value chain; Value in health

PMID:
24440285
DOI:
10.1016/j.autrev.2014.01.051
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center